年轻年龄对上皮性卵巢癌铂类反应的影响:大型单机构登记研究结果
该研究在Gustave Roussy对1990至2009年间治疗的EOC患者进行长期随访,将≤30岁年轻患者与按FIGO分期、组织学和手术残留病灶匹配的≥40岁患者比较。年轻患者以早期FIGO分期和低级别浆液性或黏液性组织学为主,但铂类化疗反应率显著低于年长患者(ORR 29% vs 84%,p=0.0002)。
要点
- 年轻EOC患者多诊断为早期FIGO分期及低级别浆液性或黏液性组织学。
- 年轻患者铂类化疗客观缓解率显著低于匹配的年长患者(29% vs 84%,p=0.0002)。
- 高级别肿瘤年轻患者5年和10年PFS为0%,年长患者为30%。
核心结论
- 年轻EOC患者多处于早期FIGO分期且为低级别浆液性或黏液性组织学,但肿瘤对铂类化疗显著更耐药。
研究设计与样本
- 单机构登记研究,纳入1990至2009年在Gustave Roussy治疗的EOC患者,将≤30岁患者与按FIGO分期、组织学、手术残留病灶及诊断日期(以2000年为界)随机匹配的≥40岁患者比较。
- 年轻组68例,年长匹配组111例,中位随访72个月(范围11-288个月)。
主要发现
- 年轻组低级别(浆液性和子宫内膜样)肿瘤占52%(n=35),黏液性肿瘤中浸润性占23%(n=16)、膨胀性占12%(n=8),高级别肿瘤仅占7%(n=5)。
- 早期FIGO I/II期疾病占53%(n=36)。
- 年轻患者铂类化疗客观缓解率低于年长匹配患者(29% vs 84%,p=0.0002)。
- 高级别肿瘤年轻患者5年和10年PFS为0%,年长患者为30%。
- 总体年轻与年长患者间PFS(中位4.9 vs 9.8个月,p=0.58)和OS(未达到 vs 15.3个月,p=0.47)无差异。
临床怎么用
- 对年轻EOC患者应认识到其铂类化疗反应可能较差,需关注耐药风险并个体化治疗决策。
局限性
- 单机构回顾性登记研究,样本量有限(年轻组68例),未发现遗传学异常可能受检测方法限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In young women, EOC is a rare disease with an uncertain genetic and biological substrate. METHODS: We report a long follow-up of EOC patients treated at Gustave Roussy between 1990 and 2009. We matched young patients aged ≤30 years to randomly selected older patients aged ≥40 years according to known prognostic factors (i.e. FIGO stage, histology and surgical residual disease) and the date of diagnosis with a threshold at the year 2000 to balance the treatment procedures. RESULTS: EOC was diagnosed in 68 patients aged ≤30 years matched with 111 patients aged ≥40 years. Low-grade (LG) (i.e. serous and endometrioid) (52%, n = 35) and mucinous (i.e. 23%, n = 16 infiltrative and 12% n = 8 expansile) tumors are prevalent. High-grade (HG) tumors are rare (7%, n = 5). Early stage diseases (53%, n = 36 FIGO I/II) are predominant. Response to platinum based chemotherapy is observed to be inferior in young patients as compared to matched older patients (ORR, 29 vs 84% p = 0.0002). For HG tumors the PFS is of 0% at 5 and 10 years in younger as compared to 30% in older patients. No difference in PFS (median 4.9 vs 9.8 ms, p = 0.58) and OS (not reached vs 15.3 ms, p = 0.47) is found overall among younger and older patients respectively. The median follow-up was 72 months (range, 11-288 months). No genetic abnormalities were found. CONCLUSIONS: Young EOC patients are most often diagnosed at an early FIGO stage with LG serous or mucinous histology. Tumors are significantly more resistant to platinum-based chemotherapy in younger patients.
引用
- Michels J, Genestie C, Dunant A, et al. Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry. Gynecol Oncol. 2020. PMID: 33059915. doi:10.1016/j.ygyno.2020.09.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。